MESH Interactive Ag.

Nov 4th, MESH's @BillSchick and Katherine King French, Director of Strategy at Smith+Nephew, will lead an MDG of Boston Lunch & Learn Masterclass: Why Great Science Still Fails Online | November 4th | 12–1 PM ET Register at eventbrite.com/e/why-great-s… #MedTech #Biopharma

How well have you pressure-tested the assumptions behind your commercialization plan? The problem you’re solving. The evidence you’re building. The traction you’re seeing. The story you’re telling investors. The path to adoption.

linkedin.com/pulse/i-can-alm… #MedTech #Biotech #FDA #Commercialization #MedicalDevices

Passion for the science matters. So does knowing the problem you’re solving, who the buyer is, and what could prevent adoption. Read Bill's newsletter where he shares 6 warning signs he’s learned to watch for after nearly 30 years working with customers in regulated industries.

Regulatory assumptions go unchallenged. Customer research starts validating what the team already wants to believe. Commercial planning gets pushed behind product dev. Those decisions can shape the regulatory path, product strategy, and whether customers will ultimately adopt.

Some of the most expensive problems in medtech and biotech start long before an FDA submission is made. Early-stage teams are moving fast, resources are limited & some decisions get pushed to later. The trouble comes when “later” involves choices that become harder & expensive.

In his latest LI newsletter, @BillSchick looks at how to identify those voices and build a process around their expertise. Read: Who Should Be the Thought Leader for Your Company? linkedin.com/pulse/who-shoul… #medtech #lifesciences #founders #startups #thoughtleadership

The people closest to customer problems often ask the best questions, challenge assumptions, and explain complex ideas in ways people can use. If those voices stay out of your content, the result can become another stream of product info and familiar industry talking points.

Some of your company’s most useful perspectives may never make it into your marketing. In medtech, biotech, and other technical industries, the person with the biggest title isn’t always the person with the most useful perspective for customers.

When: August 26th, 12–1 PM ET Location: Online Tickets: $10 Register at: eventbrite.com/e/why-great-s… #MedTech #Biopharma #Commercialization

The session combines research, market data + real-world company examples with a practical founder workbook designed to help attendees pressure-test their own plans. The goal: spot the risks, challenge the assumptions, take action.

Bill and Kate bring complementary perspectives across startup growth, investment, commercialization, market strategy and global MedTech leadership. Together, they’ll look at where risk can hide—and how teams can challenge assumptions before costly decisions get locked in.

Next week, MESH Founder Bill Schick and Katherine King French, Director of Strategy at Smith+Nephew, are teaming up for an @MDGBoston Lunch & Learn: Why Great Science Still Fails A look at 7 costly mistakes before a raise, pilot or launch.

The decisions that derail commercialization rarely look like mistakes at first. More often, they look like reasonable assumptions—about the problem, the market, what investors need to hear, what evidence matters, and what will ultimately drive adoption.

For founders developing medical devices, diagnostics, or consumer health products, this conversation offers useful questions to consider early. Watch the episode: youtu.be/9UcOoSVb2B0 #MedTech #ConsumerHealth #MedicalDevices #Diagnostics #LifeSciences #HealthcareInnovation

They discuss: - Starting with a real consumer problem - Setting clear requirements before engineering begins - Making regulated technology easier to use - Navigating FDA, funding, and market adoption

Product adoption starts long before launch. In the latest episode of LifeSci Continuum, @BillSchick talks with @AnywhereDx co-founders Nathalya Mamane and @michaelmina_lab about building an at-home diagnostic families would actually buy and use.

A strong story helps them see the opportunity, understand the timing, and remember why your company matters. For many #startups, the opportunity is already there. The challenge is making it easy for someone else to see. #MedTech #MedDevice #LifeSciences #MESHLife #HowToMESH

Use data to support the story. Market size, traction, customer behavior, and proof points should make the opportunity easier to understand and easier to believe. A strong pitch gives people the facts.

It also needs to show: Why the current options fall short Why the opportunity matters now How your product changes the outcome That sequence helps the audience understand the opportunity before they evaluate the product.